Prevalence of CD30 immunostaining in neoplastic mast cells
Sign Up to like & getrecommendations! Published in 2018 at "Medicine"
DOI: 10.1097/md.0000000000010642
Abstract: Abstract Mastocytosis is a rare disease characterized by clonal neoplastic proliferation of mast cells (MCs). It ranges from skin lesions as cutaneous mastocytosis (CM) which may spontaneously regress to highly aggressive neoplasms with multiorgan involvement… read more here.
Keywords: cd30; cd30 expression; mast cells; mast ... See more keywords
CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy.
Sign Up to like & getrecommendations! Published in 2023 at "Histopathology"
DOI: 10.1111/his.14910
Abstract: Chimeric antigen receptor (CAR) T-cells anti-CD30 is an innovative therapeutic option that has been used to treat cases of refractory/relapsed (R/R) classic Hodgkin lymphoma (CHL). Limited data are available regarding the CD30 expression status of… read more here.
Keywords: therapy; expression; car; cd30 expression ... See more keywords
CD30 expression in cutaneous lesions of systemic mastocytosis: clinical, biological and histopathological analysis of 27 patients
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.15633
Abstract: Mastocytosis is a composite group of heterogeneous diseases defined by the accumulation of abnormal mast cells (MCs) in various tissues. Cutaneous and bone marrow tissues are the most frequently infiltrated in adult patients with systemic… read more here.
Keywords: cd30 expression; mastocytosis; cutaneous lesions; systemic mastocytosis ... See more keywords
Response to A+CHP by CD30 expression in the ECHELON-2 trial.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.7538
Abstract: 7538 Background: Brentuximab vedotin (BV) is an antibody-drug conjugate that targets CD30. The ECHELON-2 (E-2) study demonstrated significantly longer progression-free and overall survival with BV plus cyclophosphamide, doxorubicin, and prednisone (A+CHP) versus CHOP in frontline… read more here.
Keywords: expression; response; chp; cd30 ... See more keywords
Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.7543
Abstract: 7543 Background: Brentuximab vedotin (BV), an antibody-drug conjugate targeting CD30, has been evaluated in multiple trials in patients (pts) with peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), or B-cell lymphoma. We examined the ability… read more here.
Keywords: cd30 expression; cell lymphoma; response; expression ... See more keywords